LUYE PHARMA (02186) · Company profile · Eqvero

LUYE PHARMA

02186HKEX

Unit: CNY	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	6.31 bn CNY	6.06 bn CNY	6.14 bn CNY	5.98 bn CNY	5.2 bn CNY
Cost of revenue	1.31 bn CNY	1.23 bn CNY	1.24 bn CNY	1.17 bn CNY	1.22 bn CNY
Research and development expense	413.92 m CNY	498.59 m CNY	586.16 m CNY	857.34 m CNY	683.16 m CNY
Selling, general and administrative expense	2.51 bn CNY	2.4 bn CNY	2.7 bn CNY	2.4 bn CNY	2.28 bn CNY
Operating profit after depreciation	1.22 bn CNY	1.14 bn CNY	887.44 m CNY	789.14 m CNY	363.4 m CNY
Operating profit before depreciation	2.06 bn CNY	1.93 bn CNY	1.59 bn CNY	1.46 bn CNY	945.38 m CNY
EBIT	1.22 bn CNY	1.14 bn CNY	887.44 m CNY	789.14 m CNY	363.4 m CNY
EBITDA	2.06 bn CNY	1.93 bn CNY	1.59 bn CNY	1.46 bn CNY	945.38 m CNY
Interest expense	686.6 m CNY	561.79 m CNY	675.45 m CNY	471.76 m CNY	399.46 m CNY
Profit before tax	944.64 m CNY	839.22 m CNY	700.1 m CNY	669.76 m CNY	-74.56 m CNY
Income tax expense	238.98 m CNY	194.21 m CNY	161.02 m CNY	86.47 m CNY	70.23 m CNY
Income before extraordinary items	618.75 m CNY	471.89 m CNY	532.61 m CNY	604.81 m CNY	-134.39 m CNY

Quotes are end-of-day data. Content is for research purposes and is not investment advice.